Cancer Drug Responses Greensboro NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Lennis Pearcy Livesay, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Sc Sch Of Med, Columbia Sc 29208
Graduation Year: 1985

Data Provided by:
Adrian A Caracioni, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Inst De Med, Timisoara, Romania
Graduation Year: 1987

Data Provided by:
Firas N Shadad
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Hematology / Oncology

Data Provided by:
Justin Ja-Li Wu, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1990

Data Provided by:
Donald Scott Murinson
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Peter Robert Ennever, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1988

Data Provided by:
Gustav Charles Magrinat, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1987

Data Provided by:
Nigel Thomas Goodchild, MD
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ London, St Bartholomew'S Hosp Med Coll, (See 917-31)
Graduation Year: 1969

Data Provided by:
Lauretta Ifeoma Odogwu
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Kalsoom Kausar Khan
(336) 832-1100
501 N Elam Ave
Greensboro, NC
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com